Regeneron
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
CEOLeonard S. Schleifer
CEOLeonard S. Schleifer
Employees15,106
Employees15,106
HeadquartersTarrytown, New York
HeadquartersTarrytown, New York
Founded1988
Founded1988
Employees15,106
Employees15,106
REGN Key Statistics
Market cap58.56B
Market cap58.56B
Price-Earnings ratio14.00
Price-Earnings ratio14.00
Dividend yield0.32%
Dividend yield0.32%
Average volume857.52K
Average volume857.52K
High today$552.00
High today$552.00
Low today$541.50
Low today$541.50
Open price$550.00
Open price$550.00
Volume1.31M
Volume1.31M
52 Week high$1,211.20
52 Week high$1,211.20
52 Week low$476.49
52 Week low$476.49
REGN News
TipRanks 8h
Regeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough in Eosinophilic Gastritis TreatmentRegeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your In...
TipRanks 2d
Regeneron Advances Melanoma Treatment with New Phase 2 TrialRegeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...
TipRanks 3d
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for CRSwNPRegeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your In...
Analyst ratings
70%
of 27 ratingsBuy
70.4%
Hold
25.9%
Sell
3.7%
More REGN News
Simply Wall St 7d
Accelerated FDA Approval of Lynozyfic May Change the Case for Investing in RegeneronRegeneron Pharmaceuticals recently received accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed or refractory multiple mye...
People also own
Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.